Summary:
- Vaxart, Inc. provided a business update and reported its full-year 2022 financial results, highlighting its progress in developing oral COVID-19 and other vaccine candidates.
- The company reported positive data from its Phase 2 clinical trial of its oral COVID-19 vaccine candidate, showing it was well-tolerated and generated a robust immune response.
- Vaxart is also advancing its pipeline of other oral vaccine candidates, including for norovirus and seasonal influenza, and plans to initiate additional clinical trials in 2023.